Posaconazole for prophylaxis of invasive fungal infections:a meta-analysis
HUANG Jin-Long
XIAO Shi-Ji
TIAN Li-Hong
ZHANG Yuan-Yuan
ZHOU Hua-Rong
SHEN Jian-Zhen
Abstract：Objective To assess the efficacy and safety of posaconazole for prophylaxis of invasive fungal infections.Meth-ods Databases such as PUBMED,Medline,Embase,Cochrane Library,SinoMed,CNKI,VIP Information and conference proceedings were searched for relevant randomized controlled trials (RCTs)about posaconazole for prophylaxis of invasive fungal infections.The cut-off time is December 2014.And reference of the included articles were also manually searched.Quali-ty of included studies were assessed and data of which were extracted.Both Review Manager 5.2 and Stata 12.0 software were used.Results Four RCTs which included 1 476 patients met the search criteria were assessed.Meta analysis results:the posaconazole group significantly reduced:the IFI rate[RR=0.41,95%CI (0.27,0.63),P <0.000 01],especially in prophylaxis for invasive aspergillosis (posaconazole vs fluconazole,P <0.000 1);and mortality from IFI[RR=0.32,95%CI (0.1 5,0.67), P =0.002<0.05].However,no significant differences were observed in adverse reactions,therapy discontinued because of ad-verse reactions,all-cause mortality rate between posaconazole and controlled groups (P >0.05).For subgroup analysis,there was no significant difference in both the rates of adverse reactions and invasive candidiasis infection between posaconazole and fluconazole (P >0.05).Conclusion Posaconazole can be used as a good alternative of amphotericin B lipid complex,flucon-azole or itraconazole for prophylaxis of invasive fungal infections.Posaconazole significantly improves the effect of prophylaxis and decreases IFI associated mortality but with no risk of increase in adverse events.
Keywords：posaconazoleIFIRCTsystematic reviewMeta-analysis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 357-364 )